Literature DB >> 3654663

The L- and R-type isozymes of rat pyruvate kinase are produced from a single gene by use of different promoters.

T Noguchi1, K Yamada, H Inoue, T Matsuda, T Tanaka.   

Abstract

cDNA clones for rat R-type pyruvate kinase and a genomic clone encoding both L- and R-type isozyme mRNAs were isolated. Their sequences were compared with that of the L-type isozyme cDNA to determine the sequences of mRNA and protein of the R-type isozyme and the organizations of the L- and R-type genes. Results showed that the R-type isozyme mRNA had an identical nucleotide sequence to that of the L-type except in the 5'-terminal region including the coding sequence and the length of the 3'-untranslated region. The sequence upstream of the 5th coding residue of the L-type was replaced by a 98-nucleotide coding sequence plus a 5'-untranslated region in the R-type isozyme. Therefore, the R-type subunit consists of 574 amino acids, which is 31 residues longer than the L-type at the amino terminus. The pyruvate kinase L gene is present as a single copy per haploid genome and is composed of 12 exons and 11 introns with a length of about 9.3 kilobase pairs. The first (exon R) and second (exon L) exons encode the 5'-terminal sequences specific for the R- and L-types, respectively. The remaining downstream exons encode a sequence common to both isozymes. The last exon contains the entire 3'-untranslated region, including several putative polyadenylation signals. Alternative use of these signals is reported to be responsible for generation of multiple mRNA species for the L-type, whereas the R-type uses only the first signal. The cap site is mapped 16 nucleotides upstream from the translation initiation site for the L-type, whereas multiple cap sites were suggested for the R-type. The canonical promoter of the TATA box was identified in the upstream sequence of exon L, but not in that of exon R. Instead, the 5'-flanking region of exon R contained another promoter sequence of the CAT box. Thus, we conclude that the L- and R-type isozymes of pyruvate kinase are produced from a single gene by use of different promoters.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3654663

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  88 in total

1.  Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Authors:  Jian-kang Jiang; Matthew B Boxer; Matthew G Vander Heiden; Min Shen; Amanda P Skoumbourdis; Noel Southall; Henrike Veith; William Leister; Christopher P Austin; Hee Won Park; James Inglese; Lewis C Cantley; Douglas S Auld; Craig J Thomas
Journal:  Bioorg Med Chem Lett       Date:  2010-04-11       Impact factor: 2.823

2.  2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Authors:  Martin J Walsh; Kyle R Brimacombe; Henrike Veith; James M Bougie; Thomas Daniel; William Leister; Lewis C Cantley; William J Israelsen; Matthew G Vander Heiden; Min Shen; Douglas S Auld; Craig J Thomas; Matthew B Boxer
Journal:  Bioorg Med Chem Lett       Date:  2011-09-14       Impact factor: 2.823

Review 3.  Alterations of metabolic genes and metabolites in cancer.

Authors:  Eric K Oermann; Jing Wu; Kun-Liang Guan; Yue Xiong
Journal:  Semin Cell Dev Biol       Date:  2012-01-28       Impact factor: 7.727

4.  Cytosolic thyroid hormone-binding protein is a monomer of pyruvate kinase.

Authors:  H Kato; T Fukuda; C Parkison; P McPhie; S Y Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

5.  Pyruvate Kinase Muscle Isoenzyme 2 (PKM2) Expression Is Associated with Overall Survival in Pancreatic Ductal Adenocarcinoma.

Authors:  Natalie A Lockney; Manchao Zhang; Yanzhen Lu; Sabrina C Sopha; M Kay Washington; Nipun Merchant; Zhiguo Zhao; Yu Shyr; A Bapsi Chakravarthy; Fen Xia
Journal:  J Gastrointest Cancer       Date:  2015-12

6.  Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation.

Authors:  Sophia Y Lunt; Vinayak Muralidhar; Aaron M Hosios; William J Israelsen; Dan Y Gui; Lauren Newhouse; Martin Ogrodzinski; Vivian Hecht; Kali Xu; Paula N Marín Acevedo; Daniel P Hollern; Gary Bellinger; Talya L Dayton; Stefan Christen; Ilaria Elia; Anh T Dinh; Gregory Stephanopoulos; Scott R Manalis; Michael B Yaffe; Eran R Andrechek; Sarah-Maria Fendt; Matthew G Vander Heiden
Journal:  Mol Cell       Date:  2014-12-04       Impact factor: 17.970

7.  Identification of small molecule inhibitors of pyruvate kinase M2.

Authors:  Matthew G Vander Heiden; Heather R Christofk; Eli Schuman; Alexander O Subtelny; Hadar Sharfi; Edward E Harlow; Jun Xian; Lewis C Cantley
Journal:  Biochem Pharmacol       Date:  2009-12-11       Impact factor: 5.858

8.  PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.

Authors:  Wenjuan Li; Joan Liu; Yunfeng Zhao
Journal:  Mol Carcinog       Date:  2012-12-19       Impact factor: 4.784

9.  Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase.

Authors:  Matthew B Boxer; Jian-kang Jiang; Matthew G Vander Heiden; Min Shen; Amanda P Skoumbourdis; Noel Southall; Henrike Veith; William Leister; Christopher P Austin; Hee Won Park; James Inglese; Lewis C Cantley; Douglas S Auld; Craig J Thomas
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

10.  Analysis of pyruvate kinase-deficiency mutations that produce nonspherocytic hemolytic anemia.

Authors:  L Baronciani; E Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.